Survodutide
A dual GLP-1 / glucagon agonist showing strong weight-loss and MASH-resolution data.
How it works
Survodutide (BI 456906) activates GLP-1 and glucagon receptors. Glucagon agonism amplifies hepatic lipid oxidation and basal metabolic rate.
Reported benefits
- 19.0% mean body-weight reduction at 46 weeks in phase-2 obesity trial
- 83% MASH resolution at 48 weeks (phase-2 NASH study)
Dosage & administration
Investigational. Phase-2 used weekly subcutaneous escalation up to 4.8 mg.
Dosing information is summarised from published clinical and pre-clinical literature for research purposes only and does not constitute medical advice.
Clinical & pre-clinical evidence
Survodutide for treatment of obesity, phase-2
The Lancet Diabetes & Endocrinology · 2024
Up to 19.0% weight loss over 46 weeks.
Safety & warnings
- GI side effects most common
- Modest heart-rate increase
For research use. Consult a licensed clinician before any human application. Not for use in pregnancy, lactation, or active malignancy without specialist supervision.
Available presentations
10 mg
SUR10
Box of 10 · $888
Single vial · $1,776
Related guides
Tirzepatide
A first-in-class dual GIP and GLP-1 receptor agonist that has reset the standard for pharmacologic weight loss.
Semaglutide
The long-acting GLP-1 analogue that opened the modern era of injectable weight management.
Retatrutide
An investigational triple agonist of GLP-1, GIP, and glucagon receptors producing unprecedented weight loss in phase-2 data.